Business Wire

Brain Corp Continues European Growth, Demonstrates ‘Inventory Scan’ Technology with Tennant Company, a First-of-its-kind Robotic Solution for Automated Analytics in Retail

28.4.2022 11:00:00 EEST | Business Wire | Press release

Share

Brain Corp, an artificial intelligence (AI) company creating transformative core technology in robotics, and Tennant Company, today announced the European demonstration of Inventory Scan, a powerful new data capture accessory that will be fitted to Tennant’s autonomous floor scrubbers to autonomously scan and report key detail on in-store inventory.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220428005188/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Brain Corp Demonstrates ‘Inventory Scan’ Technology with Tennant Company at Interclean (Photo: Business Wire)

"By adding Inventory Scan to new or existing robotic scrubber fleets, retailers are immediately able to access critical in-store inventory data in near real-time," said Dave Ross, Vice President of Business Development at Brain Corp. "Knowing where an item is, if it’s in stock, if it’s in the correct location, if the price is accurate, and more allows managers to operate stores with a new level of efficiency while providing optimal shopping experiences for their customers. Based on the success we’ve seen in the US with the technology, we are excited to get feedback from those in the European market.”

Utilizing a first-of-its-kind, multi-purpose design, the powerful new scanning accessory will be fitted to Tennant’s floor scrubbers powered by Brain Corp’s BrainOS autonomy software platform. The new, cloud-connected Inventory Scan tower is able to capture data as it moves autonomously around the store. Reports are then delivered to the store managers, providing numerous insights including: verification of pricing accuracy, planogram compliance, product stock levels and product localization. Each function negates the need for time-consuming and potentially inaccurate manual processes, which often lead to lost revenue opportunities, waste caused by overordering and not enough attention given to shoppers.

“The new integrated inventory analytics accessory is filling a much-needed AI and data process gap for retailers,” said Maggie Koester, Global Product Manager at Tennant Company. “What makes this solution compelling is the ability to integrate with retailers’ inventory management systems utilizing their existing floor scrubbers. By adding data collection functionality to these machines, we are dramatically improving how stores operate. Inventory Scan allows retailers to be more efficient and effective by reducing the disruption of labor-intensive manual approaches. Our vision is that data collection and floor care become fully automated so our customers can focus on managing their businesses.”

Interclean 2022 to Host the Unveiling of the Technology in Amsterdam

Inventory Scan will have its European introduction on May 10-13, 2022 at the RAI Centre in Amsterdam, on Brain Corp stand - Hall 7, Booth 108.

"This new product marks the beginning of realizing the next phase in our company's vision and continued growth in Europe as well as the US," said Dr. Eugene Izhikevich, CEO of Brain Corp. "We are actively taking BrainOS-powered robots from primarily task-oriented machines to in-store data acquisition platforms. This delivers critical insights and this will add significant ROI for European retailers as we continue to expand our activity in Europe and beyond."

Brain Corp Sees 100% Year-on-year Growth in European Countries Deploying BrainOS-powered Robots

Partnering with many of the world’s leading OEMs (Original Equipment Manufacturers) including Minuteman, Karcher, Nilfisk and Tennant, autonomous robotic scrubbers, powered by Brain Corp’s AI operating system BrainOS®, are now operational across multiple sectors in 16 European countries.

New countries seeing robotic deployments include Belgium, Denmark, Finland, Luxembourg, Norway and Switzerland. Countries implementing the largest numbers of autonomous robots include France, Spain, Portugal, Italy, Germany, the UK, and the Netherlands.

“There’s no doubt that we’re starting to see the tipping point where the integration of robotics with human teams has gone beyond a novelty and become a practical solution for maintaining sustainable operations,” said Michel Spruijt, SVP International Business at Brain Corp. “We’re seeing significant increases in demand across multiple industry sectors which have been impacted most severely by labor shortages and increased operational strain as a result of the pandemic. Autonomous robotics have proven themselves to be a very effective and welcome solution to these growing problems.”

In 2021, the BrainOS®-powered fleet of autonomous mobile robots hit a major milestone of 500 million square feet covered (46.45 million square meters) autonomously in Europe. In total, over 46,000 hours were given back to workers during the year with the most significant growth coming within retail, logistics, and warehousing sectors.

About Brain Corp

Brain Corp is the global leader in robotic AI software that powers the largest fleet of autonomous mobile robots (AMRs) operating in commercial public spaces. Global OEM partners use the company’s cloud-connected platform, BrainOS®, to create scalable, self-driving robots that are used by end customers to clean floors, move inventory, and sense environmental data - turning manual operations into automated workflows. Fortune 500 brands across multiple verticals benefit from the growing portfolio of BrainOS®-powered robots and our industry-leading privacy, safety and efficiency tools that make managing and scaling automation easier. Brain Corp currently powers more than 20,000 AMRs, representing the largest fleet of its kind in the world.

For more information, visit www.braincorp.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Josh Stanbury | josh@sjspr.co | 416-628-7441

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye